Ivermectin drug-induced liver injury

Abstract

Ivermectin remains a popular, albeit unproven, therapy used in both the prevention and treatment of COVID‑19. We discuss a patient who developed jaundice and a liver injury 3 weeks after initiating ivermectin for COVID‑19 prevention. Liver histology demonstrated a pattern of injury that was both portal and lobular, with a bile ductulitis with marked cholestasis. She was managed with low‑dose corticosteroids, later tapered, and withdrawn. She remains well a year after presenting.